

Breast Cancer Trails

To go back to the main page, click [here](#)

S.No	Drug Name	Biological Name	Developer	Current Development Phase	Additional Information	Start Date	Completion Date	Source
11	-	carcinoembryonic antigen RNA-pulsed DC cancer vaccine	Duke University, National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic cancer that has not responded to previous treatment.	2000	2009	Source
12	ETBX-011	AD5 CEA Vaccine	Etubics Corporation	I/II	The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D) or ETBX-011 and is made by Etubics. This vaccine is based on a virus called an adenovirus but it has been changed to express the protein CEA that is found on some cancer cells. Therefore, the vaccine can tell the immune system to attack cancer cells which make CEA. The investigators are trying to determine whether giving this virus is safe and whether this causes a strong immune system attack on the cancer. ETBX-011 is an investigational drug.	-	-	-
13	cyclophosphamide	HER2/neu peptide vaccine	Fred Hutchinson Cancer Research Center	I/II	This phase I/II trial is studying the side effects and best dose of vaccine therapy in treating patients with stage IV breast cancer	2008	2015	Source
14	-	Investigational Cancer Vaccine	GlaxoSmithKline	I	This trial will test how safe this vaccine is. It also tests whether its introduction induces an immune response by stimulating the patient's own immune system to recognize a specific target molecule called HER2, which is overexpressed in many breast cancers.	2003	Ongoing	Source
15	-	Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated	Hadassah Medical Organization	I/II	This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with colorectal, gastric, ovarian, breast or lung epithelial cancer	-	-	Source
16	-	DPX-0908	ImmunoVaccine Technologies, Inc.	I	To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.	-	-	-
17	-	PSMA/PRAME	MannKind Corporation	I	Completed The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to	2007	2009	Source

					stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.			
18	-	aldesleukin, allogeneic large multivalent immunogen breast cancer vaccine	Masonic Cancer Center, University of Minnesota	II	This phase II trial is studying how well giving vaccine therapy together with aldesleukin works in treating women with metastatic breast cancer.	2008	2013	Source
19	-	EphA2 Vaccine/ MEDI-543	MedImmune	I	-	-	-	-
20	-	V934/V935	Merck	I	Completed. This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.	2008	2011	Source
21	-	Stimuvax	Oncothyreon	III	Suspended	-	-	-
22	-	BCG vaccine, CD80 breast cancer vaccine, sargramostim	Providence Cancer Center, Earle A. Chiles Research Institute	I	Phase I trial to study the effectiveness of vaccines made from breast cancer cells in treating women with metastatic breast cancer.	1996	Ongoing	Source
23	Trastuzumab, Cyclophosphamide	Allogeneic GM-CSF-secreting breast cancer vaccine	Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI)	II	Active: This is a feasibility study to examine combination therapy with Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine in patients with Stage IV HER-2/neu-overexpressing breast cancer.	2006	2013	Source
24	cyclophosphamide, doxorubicin hydrochloride	allogeneic GM-CSF-secreting breast cancer vaccine	Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI)	I	This phase I trial is studying the side effects and best dose of cyclophosphamide and doxorubicin when given with vaccine therapy in treating women with stage IV breast cancer.	2004	2008	Source
25	-	Dendritic Cell Vaccination	Southern Cancer Center	I	The study uses a molecule or particle that is found only on cancer cells and is unique to cancer cells, as it is not detected on normal tissue. The molecule is known as "oncofetal antigen" or OFA. Because OFA is unique to cancer, the investigators feel OFA could be used to educate the patients' own defenses to more effectively fight the cancer on her own, he or she is harboring.	2008	2015	Source
26	-	AdhTAP	TapImmune	Preclinical	-	-	-	-
27	-	CEA DNA Cancer Vaccine	Vical/Merck	I	-	-	-	-
28	cyclophosphamide	allogeneic GM-CSF-secreting breast cancer vaccine, recombinant interferon alfa	Wiseman Research Initiatives, LLC; National Cancer Institute (NCI)	I/II	Phase I trial to study the effectiveness of combining vaccine therapy with interferon alfa and cyclophosphamide in treating patients who have stage IV breast cancer.	2004	2010	Source